Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs, Inc. (NASDAQ: BIOA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic diseases by targeting the biology of human aging. Company announcements highlight progress in its lead NLRP3 inhibitor program, preclinical obesity programs, and collaborations with larger pharmaceutical partners.
A key focus of recent news is BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor. BioAge has reported interim data from an ongoing Phase 1 single and multiple ascending dose trial, including information on safety, pharmacokinetics, and pharmacodynamic effects on inflammatory biomarkers such as IL-1β, hsCRP, IL-6, and fibrinogen in healthy volunteers and obese participants with elevated inflammation.
News updates also cover BioAge’s broader pipeline and strategy. The company issues releases on the advancement of long-acting injectable and oral small-molecule APJ agonists for obesity, including a nanobody APJ agonist under an exclusive option agreement and a portfolio of orally active APJ agonists. In addition, BioAge communicates developments in its discovery platform based on human longevity data and its multi-year collaborations with Novartis and Lilly ExploR&D on metabolic aging targets.
Investors following BIOA news can expect coverage of clinical milestones for BGE-102, preclinical and regulatory progress for APJ agonist programs, financial results, and participation in healthcare and biotechnology conferences. This page aggregates those updates so readers can review BioAge’s clinical data disclosures, partnership announcements, and strategic commentary in one place.
On January 30, 2023, BioArctic AB announced that its partner, Eisai, received Priority Review designation from the Japanese Ministry of Health for the marketing application of lecanemab (LEQEMBI™), an antibody for Alzheimer's disease (AD). The application, submitted on January 16, 2023, is based on results from the Phase 3 Clarity AD study, which demonstrated a significant reduction in clinical decline in early AD. Lecanemab has also received accelerated FDA approval in the U.S. for AD treatment. BioArctic is entitled to payments and royalties from lecanemab's sales, having no development costs associated with the drug.
BioArctic AB announced that its partner Eisai received acceptance from the European Medicines Agency (EMA) for a marketing authorization application (MAA) for lecanemab (brand name LEQEMBI) targeting early Alzheimer's disease.
This approval allows BioArctic to receive a milestone payment of MEUR 5. In the U.S., the drug received accelerated approval by the FDA on January 6, 2023, and Eisai is pursuing traditional approval based on positive Phase III results.
BioArctic has no developmental costs for lecanemab and is entitled to royalties on global sales and milestone payments.
On January 25, 2023, BioArctic AB announced the upcoming publication of its fourth quarter report for October-December 2022, set for February 3, 2022, at 08:00 CET. The company will host an audiocast at 09:30 CET the same day, where CEO Gunilla Osswald and CFO Jan Mattsson will present the report and participate in a Q&A session. BioArctic focuses on innovative treatments for neurodegenerative diseases, collaborating with global partners. Their Class B shares trade on Nasdaq Stockholm under the ticker BIOA B. For more details, visit their corporate website.
On January 16, 2023, BioArctic AB announced that its partner, Eisai, has submitted a marketing authorization application for lecanemab (brand name: LEQEMBI™) for early Alzheimer's disease treatment in Japan. The application follows Phase 3 Clarity AD study results, showing significant clinical decline reduction. BioArctic is entitled to a milestone payment of MEUR 5 upon acceptance by the PMDA. The FDA granted accelerated approval for lecanemab on January 6, 2023, with a supplemental application for full approval submitted on the same date. Eisai manages global development, while BioArctic prepares for commercialization in the Nordics.